Pharmaceutical News

RSS

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Disabling a cancer-causing pathway and administering an immune-molecule-based mop-up therapy eradicated a specific type of breast tumor in mice, according to researchers in the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best performing dose of 60 µg per protein / 75 µg of Matrix-M2TM adjuvant, GEN-003 demonstrated a statistically significant 58 percent reduction from baseline in the viral shedding rate (p < 0.0001), the primary endpoint of the study.

7 Oct 2015

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.

7 Oct 2015

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Solix Algredients introduces Solasta Astaxanthin to B2B marketplace

Solix Algredients, Inc. has introduced Solasta Astaxanthin to the B2B ingredients marketplace. Solasta is a natural astaxanthin extract produced from the microalga Haematococcus pluvialis, the richest natural source of the antioxidant. Research has shown that algal astaxanthin has superior antioxidant activity compared to other well-known antioxidants.

7 Oct 2015

Influenza-related pneumonia hospitalizations could be prevented through influenza vaccination

More than half of hospitalizations due to influenza pneumonia could be prevented by influenza vaccination, according to a study led by investigators at Vanderbilt University Medical Center, published this week in the Journal of the American Medical Association.

7 Oct 2015

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.

6 Oct 2015

Acetaminophen Awareness Coalition issues safety message to consumers about flu medicines

With cold and flu season around the corner, consumers will soon begin to purchase medicines such as cough syrup, throat lozenges, and nasal sprays to help get relief from symptoms such as fever, coughs, congestion, and more. Many of the medicines used to treat these cold and flu symptoms can contain common drug ingredients such as acetaminophen.

6 Oct 2015

Flu vaccine significantly reduces stroke risk

The risk of suffering a stroke is significantly reduced for up to two months after receiving a flu vaccine, a major new study has shown.

6 Oct 2015

Benzodiazepines heighten risks for dementia and death

Patients taking benzodiazepines to treat psychiatric conditions should consider transitioning to other therapies because of heightened risks for dementia and death, according to clinicians from the American College of Osteopathic Neurologists and Psychiatrists.

6 Oct 2015

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

A new population-based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five-year period was not associated with an increased risk of aggressive prostate cancer. Further, risk of high-grade prostate cancer did not increase according to the total number of testosterone injections.

5 Oct 2015

Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX, an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

1 Oct 2015

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.

1 Oct 2015

Experimental drug shows promise in mice with multiple sclerosis

An experimental drug originally identified in a National Cancer Institute library of chemical compounds as a potential therapy for brain and basal cell cancers improves the symptoms of mice with a form of the debilitating neurological disorder multiple sclerosis (MS), according to new research from NYU Langone Medical Center.

1 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Antipsychotic drugs may increase the risk of death in people with Parkinson's disease psychosis (PDP), according to a new study led by researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London.

1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Survey: One-third of US women use compounded hormones at menopause

A third of US women who take hormones at menopause are using compounded hormones, shows a new national survey. These women commonly--and mistakenly--think these hormones are safer and offer more benefits than FDA-approved therapies.

30 Sep 2015

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and the circulating tumor cells that can cause a cancer to metastasize. The work was tested successfully in an animal model.

30 Sep 2015

Pharmaceutical News

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Genocea announces positive data in Phase 2 trial evaluating GEN-003 for the treatment of genital herpes

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Solix Algredients introduces Solasta Astaxanthin to B2B marketplace

Influenza-related pneumonia hospitalizations could be prevented through influenza vaccination

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Acetaminophen Awareness Coalition issues safety message to consumers about flu medicines

Flu vaccine significantly reduces stroke risk

Benzodiazepines heighten risks for dementia and death

Testosterone therapy not associated with increased risk of aggressive prostate cancer: Study

Tris Pharma announces launch of generic TUSSIONEX

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Experimental drug shows promise in mice with multiple sclerosis

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Survey: One-third of US women use compounded hormones at menopause

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News